Patients who desire a steroid-free topical agent for Atopic Dermatitis will be benefitted
Intas Pharmaceuticals, one of India’s leading pharmaceutical companies with operations across the globe has launched TOFATAS – a DCGI-approved, Tofacitinib Ointment 2 per cent w/w for the treatment of mild to moderate atopic dermatitis (AD) in patients 18 years and above having flare-ups of the disease.
“There have been no approved Topical JAK inhibitors in India available to date and the approval of TOFATAS OINTMENT 2 per cent, therefore, would help in patients who desire a steroid-free topical agent for Atopic Dermatitis, and we hope that real-world data mirrors the approvals given to this agent in India,” said Dr Kabir Sardana, MD, DNB, MNAMS, Professor (Dermatology) at the RML Hospital, Delhi.
Dr Alok Chaturvedi, Associate Executive Vice President & Head-Medical Affairs, Intas said “Intas being a frontrunner in dermatology therapy, boldly and successfully endeavoured to bridge this critical treatment gap by investing in extensive research efforts to develop and formulate TOFATAS Ointment – a drug that delivers the desired outcome and the clinical benefits for Atopic Dermatitis patients. A Phase III clinical study of TOFATAS (Tofacitinib Ointment 2 per cent w/w) in Atopic Dermatitis patients in India showed remarkable safety and efficacy.”
